Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy

Alexandra K. Rzepecki, Haiying Cheng, Beth N. McLellan

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


The relationship between treatment outcome and cutaneous toxicity induced by anticancer therapy has gained attention in the past decade. In this article, we have provided an overview of the 3 main classes of anticancer agents—specifically, molecularly targeted kinase inhibitors, immune checkpoint inhibitors, and cytotoxic chemotherapeutics—and described the data evaluating the association between cutaneous toxicity induced by these agents and survival benefit. Although preliminary studies are promising with regard to the potential role of cutaneous toxicities as a surrogate biomarker of efficacy of treatment, larger prospective studies are needed to confirm this relationship. Dermatologists have a unique opportunity to collaborate with oncologists in the multidisciplinary treatment paradigm by helping to identify and manage these dermatologic events in patients with cancer. A heightened awareness of these toxicities is critical, as it can potentially allow recognition of the efficacy of anticancer therapy and may influence treatment decisions and patient outcomes.

Original languageEnglish (US)
Pages (from-to)545-555
Number of pages11
JournalJournal of the American Academy of Dermatology
Issue number3
StatePublished - Sep 1 2018


  • biomarker
  • cancer outcome
  • cutaneous adverse event
  • cutaneous toxicity
  • oncodermatology
  • prognostic marker
  • survival

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy'. Together they form a unique fingerprint.

Cite this